JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M110637200 on March 23, 2002

J. Biol. Chem., Vol. 277, Issue 22, 19806-19810, May 31, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/22/19806    most recent
M110637200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hama, J.
Right arrow Articles by Weinstein, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hama, J.
Right arrow Articles by Weinstein, D. C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Molecular Basis of Src Kinase Specificity during Vertebrate Mesoderm Formation*

Joanne HamaDagger, Crystal SuriDagger, Tomomi Haremaki, and Daniel C. Weinstein§

From the Department of Pharmacology and Biological Chemistry, Mount Sinai School of Medicine, New York, New York 10029

Received for publication, November 5, 2001, and in revised form, March 4, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Members of the Src family of non-receptor tyrosine kinases play a critical role in mesoderm formation in the frog, Xenopus laevis, acting as required mediators downstream of the fibroblast growth factor receptor. At least four members of this gene family, Src, Fyn, Yes, and Laloo, are expressed during early embryonic development. Ectopic expression of Laloo and Fyn, but not Src, induce mesoderm in ectodermal explants, indicating that these factors are non-redundant during early vertebrate development. Here we investigate the basis for the differential activity of the Src and Laloo kinases during mesoderm formation. We demonstrate that although both Src and Laloo physically interact with the substrate protein SNT-1/FRS2alpha only Laloo phosphorylates SNT-1, an event previously shown to be required for the activity of the latter and for mesoderm induction in vivo. We show that Src is enzymatically capable of stimulating mesoderm formation, as an activated Src construct both phosphorylates SNT-1 and induces mesoderm in explant cultures. However, a chimeric Laloo construct containing a Src C-terminal tail is inactive, suggesting that the early embryo contains a specific Laloo-activating, or Src-inactivating, factor. Finally, through further chimeric analysis, we provide evidence to suggest that differences in Laloo and Src activity are also mediated by the SH2, SH3, and kinase domains of these molecules.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The mesodermal germ layer plays a fundamental role in organizing the vertebrate body axes and gives rise to the skeletal, muscular, and circulatory systems. In the frog, Xenopus laevis, members of both the transforming growth factor-beta and fibroblast growth factor (FGF)1 ligand families have been shown to play critical roles during mesoderm formation (1). In recent years, a model has emerged in which members of the Src family of non-receptor tyrosine kinases serve as central mediators of the signal transduction cascade initiated by activation of the FGF receptor. Both the Xenopus Src kinase Laloo and the related Xenopus Fyn induce mesoderm in ectodermal (animal cap) explants (2-4). Induction by these factors is blocked by reagents that inhibit signaling downstream of the FGF receptor; conversely, Src family kinase activity is required for mesoderm induction by FGF (3, 4).

The epistasis studies described above indicate that the Src kinases function as required components of the cascade triggered by the FGF receptor during mesoderm formation. The molecular interactions underlying this requirement have begun to emerge. A physical association between Laloo and the FGF receptor-associated scaffolding protein SNT-1/FRS2alpha has recently been demonstrated (5, 6). SNT-1 contains six tyrosine residues, which upon phosphorylation serve as binding sites for both the Grb2 adaptor protein and the Shp2 phosphatase (7-9). An unphosphorylatable form of SNT-1 prevents mesoderm induction by FGF downstream of Laloo, suggesting that Laloo functions to recruit Shp2 and Grb2 to SNT-1 by phosphorylation of SNT-1 (5, 6). The demonstration that an activated Laloo mutant can phosphorylate exogenous SNT-1 supports such a role for endogenous Laloo (5).

An initial challenge in elucidating the mechanism of Src kinase function during mesoderm formation has been to determine which members of this sizeable protein family are directly involved in mediating the mesoderm-inducing signal. In addition to Laloo, the Src, Fyn, and Yes kinases are also expressed during early Xenopus development (2, 10, 11). Although Xenopus Fyn activity is indistinguishable from that of Laloo, Xenopus Src, with a primary sequence very similar to that of Fyn, is completely inactive in mesoderm induction assays (4).

We have attempted to dissect the molecular basis for differences in the behavior of these related proteins, anticipating that such studies would provide us with valuable insights on the mechanisms by which these factors function during early development. Here, we demonstrate that Src, like Laloo, physically associates with SNT-1; however, although Laloo effectively phosphorylates tyrosine residues on SNT-1, Src does not. We then demonstrate that SNT-1 may serve as a Src substrate under some conditions, as an activated form of Src both induces mesoderm and phosphorylates SNT-1. We provide evidence suggesting that Src inactivity during early development is due to the action of a factor that specifically recognizes the C-terminal tail of Src but not a similar motif in Laloo. Finally, we demonstrate that the SH3, SH2, and kinase domains of Laloo may additionally contribute to differences in activity of the two molecules.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

RNA Preparation, Explant Dissection, and Cell Culture-- RNA was synthesized in vitro in the presence of the cap analog using the mMessage mMachine kit (Ambion). Microinjection, explant dissection, and culture were performed as described (12, 13).

Preparation of Laloo, Src, and SNT-1 Constructs-- SNT-1-Myc and Laloo-FLAG construction were described previously (6, 14). Src-FLAG includes the sequence DYKDDDDK at the Src C terminus. SrcY526F was generated by PCR-based mutagenesis (TACright-arrowTTC) at nucleotide 1579 of Xenopus Src. Domain-swap hybrids were constructed by PCR; domains were defined as corresponding to the following amino acids (Laloo accession number AAC31209; Xenopus Src accession number AAA49962): Laloo SH4, 1-55; Laloo SH3, 56-117; Laloo SH2, 118-232; Laloo kinase, 233-483; Laloo tail, 484-496; Src SH4, 1-85; Src SH3, 86-147; Src SH2, 148-255; Src kinase, 256-517; Src tail, 518-532.

RT-PCR-- RT-PCR was performed as described (3, 13). All primer sequences are as described (3, 12, 15).

Xenopus Co-immunoprecipitation Assay-- 50 pg of SrcY526F and 1 ng each of Laloo-FLAG, Src-FLAG, and/or SNT-1-Myc RNA were injected into the animal poles of early cleavage stage embryos. Embryos were lysed after 6 h in 500 µl of lysis buffer (20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, and 1 Complete minitablet/10 ml of buffer (Roche)). For studies examining tyrosine phosphorylation of SNT-1, lysis buffer included 1 mM sodium orthovanadate. After 30 min of incubation on ice, lysates were centrifuged twice, 2 min each at 4 °C at 14,000 × g; after each centrifugation, only the clear lysate was retained. Lysates were incubated overnight at 4 °C with 1:1000 antibody (anti-FLAG M2 monoclonal or anti-Myc tag monoclonal 9E10 (Sigma)), followed by incubation with protein A/G-PLUS-agarose (Santa Cruz Biotechnology) for 1 h at 4 °C. After four washes in lysis buffer, protein was eluted in 0.1 M glycine, pH 3.5, neutralized with wash buffer (0.05 M Tris, pH 7.4, 0.15 M NaCl), and subjected to standard SDS-PAGE and Western blotting protocols.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Src Is Expressed but Inactive in the Mesoderm during Gastrulation-- The expression patterns and activities of Xenopus FGFs are consistent with a model in which FGF pathway activation within the gastrula stage marginal zone is required for the proper response to and maintenance of mesoderm induction. Although both maternal and zygotic Xenopus src transcripts have been identified (10, 15), the localization of Xenopus src during gastrulation has not been characterized. As shown in Fig. 1A, src is present throughout the gastrula stage embryo, including in the cells of the dorsal and ventral marginal zone (Fig. 1A). Thus, Xenopus src, like laloo, is expressed in the cells of the presumptive early mesoderm, consistent with a role for these factors in mesoderm formation.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 1.   Xenopus Src is expressed in the marginal zone but is inactive in gastrula-stage mesoderm. A, RT-PCR analysis of Xenopus src (Xsrc) expression in gastrula stage explants (stage 10.5). B, RT-PCR analysis of animal caps dissected at late blastula stages and cultured until midgastrula stages. Animal caps were isolated from uninjected embryos or embryos injected with src RNA at the two-cell stage as listed. 25 ng/ml (high) and 1 ng/ml (low) bFGF were added as listed. The embryo-RT lane contains all reagents except reverse transcriptase and was used as a negative control. Ornithine decarboxylase (ODC, Ref. 23) and EF1-alpha (24) were used as loading controls. Xbra is a panmesodermal marker at this stage (16). Chordin is a dorsal mesodermal marker (25). Xwnt8 is a ventrolateral mesodermal marker (17, 18). RT-PCR data for Xbra, Chordin, and Xwnt8 expression in A was derived previously (6).

Although previous studies of Src function in mesoderm formation have been performed by introducing src transcripts into competent ectoderm, it is conceivable that Src, unlike Laloo, requires a mesodermal context for activation. To address this possibility, we examined Src activity in embryonic mesoderm. It was not possible to assay for Src function directly in the marginal zone, the site of endogenous mesoderm formation, because of the high levels of mesoderm-specific marker genes already expressed in these cells; this strong baseline expression precluded detection of additional mesoderm induction by ectopic Src. As an alternative approach, we examined whether ectopic Src could boost mesoderm generated by low levels of the mesoderm-inducing factor, basic FGF (bFGF). As shown in Fig. 1B, 25 ng/ml bFGF is a potent inducer of both the panmesodermal marker Xbrachyury (Xbra) and the ventrolateral mesodermal marker Xwnt8 (Fig. 1B, lane 1; Refs. 16-18). 1 ng/ml bFGF induces low levels of these markers (Fig. 1B, lane 2). Expression of high doses of src mRNA does not induce expression of these markers (Fig. 1B, lane 3; Ref. 4); furthermore, Src expression does not enhance mesoderm induction by 1 ng/ml bFGF (Fig. 1B, compare lanes 2 and 4). Thus, Src misexpression cannot stimulate mesoderm formation in either an ectodermal or a mesodermal context.

Src Interacts with the Laloo Kinase Substrate SNT-1/FRS2alpha -- Laloo physically interacts with SNT-1 and phosphorylates tyrosine residues on SNT-1 (5, 6). Because phosphorylatable SNT-1 is required for mesoderm induction by Laloo (5, 6), we examined whether Src inactivity in the mesoderm induction assay could be due to an inability to bind SNT-1. Towards this end, we expressed epitope-tagged SNT-1 with either tagged Laloo or Src in early cleavage stage embryos and performed co-immunoprecipitation assays on lysates from these embryos that were harvested at blastula stages. As shown in Fig. 2, both Laloo and Src physically associate with exogenous SNT-1 (Fig. 2, lanes 4 and 5). These results suggest both that endogenous Src interacts with SNT-1 and that differences in SNT-1 affinity alone are unlikely to underlie the difference in activity of these kinases during mesoderm induction.


View larger version (52K):
[in this window]
[in a new window]
 
Fig. 2.   Src interacts with SNT-1. Western blot analysis of SNT-1/Laloo and SNT-1/Src co-immunoprecipitation. Synthetic RNA from epitope-tagged constructs was injected into early cleavage stage embryos; 1 ng each of SNT-1-Myc, Laloo-FLAG, and Src-FLAG were injected as listed. Cell lysates were collected at late blastula stages. FLAG-tagged Laloo and/or Src protein was immunoprecipitated using an anti-FLAG antibody. Co-precipitation of Myc-tagged SNT-1 was detected by Western blot (top lanes). Expression of epitope-tagged Laloo, Src, and SNT-1 protein was determined by Western blot analysis of cell lysates (middle and bottom lanes).

Src Does Not Phosphorylate SNT-1-- Studies using an activated Laloo construct suggest that Laloo phosphorylates SNT-1 on one or more of the tyrosine residues that serve as SHP2 and Grb2 binding sites (5). As shown in Fig. 3, expression of wild-type Laloo similarly triggers the tyrosine phosphorylation of SNT-1 (Fig. 3, lane 3). Notably, however, ectopic expression of Src does not induce any appreciable tyrosine phosphorylation of exogenous SNT-1 (Fig. 3, lane 2). Because SNT-1 tyrosine phosphorylation is required for mesoderm induction by Laloo and in vivo, this result strongly suggests that Src fails to induce mesoderm because it does not phosphorylate tyrosine residues on SNT-1.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 3.   Laloo, but not Src, phosphorylates SNT-1. Western blot analysis of SNT-1 immunoprecipitation. Synthetic RNA from epitope-tagged constructs was injected into early cleavage stage embryos; 1 ng each of SNT-1-Myc, Laloo-FLAG, and Src-FLAG were injected as listed. Cell lysates were collected at late blastula stages. Myc-tagged SNT-1 protein was immunoprecipitated using an anti-Myc antibody. SNT-1 tyrosine phosphorylation was detected by Western blot (top lanes). Expression of epitope-tagged Laloo, Src, and SNT-1 proteins was determined by Western blot analysis of cell lysates (middle and bottom lanes).

Role of the Src C-terminal Tail-- The inability of Src to phosphorylate SNT-1 suggests that SNT-1 is an incompatible substrate for Src and/or that Src activity is inhibited during mesoderm formation. To distinguish between these possibilities, we constructed an activated Src mutant. All Src family kinases contain a C-terminal tyrosine residue that when phosphorylated significantly inhibits the function of these proteins (19). We generated a tyrosine-to-phenylalanine mutation in the corresponding residue (Tyr-526) of Xenopus Src. mRNA synthesized from this construct, SrcY526F, was first examined for its ability to induce phosphorylation of SNT-1. In co-expression assays, SrcY526F consistently phosphorylated SNT-1 on tyrosine (Fig. 4A, lane 2). Levels of SNT-1 phosphorylation were not as robust as that seen following co-expression of SNT-1 and Laloo; this may be due to differences in the levels of Laloo and SrcY526F protein expression.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 4.   Inhibition of Src and Laloo by the Src C terminus. A, Western blot analysis of SNT-1 immunoprecipitation. Synthetic RNA from epitope-tagged constructs was injected into early cleavage stage embryos; 1 ng each of SNT-1-Myc and SrcY526F were injected as listed. Cell lysates were collected at late blastula stages. Myc-tagged SNT-1 protein was immunoprecipitated using an anti-Myc antibody. SNT-1 tyrosine phosphorylation was detected by Western blot (top lanes). Expression of SNT-1 protein was determined by Western blot analysis of cell lysates (bottom lanes). B and C, RT-PCR analysis of animal caps dissected at late blastula stages and cultured until midgastrula stages. 4 ng of src, 50 pg of SrcY526F, 1 ng of LST, and 1 ng of SLT RNA were injected as listed. EF1-alpha was used as a loading control. Xbra is a panmesodermal marker. Chordin is a dorsal mesodermal marker. Xwnt8 is a ventrolateral mesodermal marker.

We next examined whether SrcY526F was active in the mesoderm induction assay. As shown in Fig. 4B, injection of 50 pg of SrcY526F RNA is sufficient to induce both Xbra and Xwnt8 expression (Fig. 4B, lane 5); 4 ng of wild-type src RNA, in contrast, produced no induction of either marker (Fig. 4B, compare lanes 1 and 5; Ref. 4). SrcY526F RNA is thus able to induce mesoderm at doses similar to those observed for activated Laloo (3).

In order to explore further the role of the Src C terminus in the regulation of mesoderm formation, we generated Src-Laloo chimeric molecules in which the C-terminal tails of the two proteins, including the regulatory tyrosine residue, were exchanged. These reagents were then tested for mesoderm-inducing activity in the animal cap assay. As shown in Fig. 4C, both Laloo with the Src tail (lane 1, LST) and Src with the Laloo tail (lane 2, SLT) are inactive. This inactivity is not due solely to the elimination of native sequence, because deletion of the tail regions of either Src or Laloo produce activated molecules of comparable potency to LalooY492F and SrcY526F (data not shown). Taken together, these results demonstrate that the Src kinase is capable of SNT-1 phosphorylation and mesoderm induction and suggest that the Src C terminus inhibits Src activity in the early embryo.

Activity of Additional Src-Laloo Chimeras-- Although the experiments described above indicate that the activated Src kinase can induce mesoderm, the inactivity of SLT suggests that there may be other regions of Laloo that preferentially activate the molecular cascade that ultimately results in mesoderm formation. To examine this possibility, we generated additional chimeric molecules in which the SH4, SH3, SH2, and kinase domains of Laloo and Src were individually exchanged. mRNA derived from these constructs were then tested in the mesoderm induction assay. As shown in Fig. 5, exchange of the SH4 domains of Laloo and Src had no effect; i.e. Laloo with the Src SH4 (Fig. 5A, lane 2, S4L) domain remained active, and Src with the Laloo SH4 (Fig. 5A, lane 1, L4S) domain remained inactive. However, Src chimeras that contain either the Laloo SH3 (Fig. 5B, lane 2, S(L3)S); SH2 (Fig. 5C, lane 2, S(L2)S); or kinase (Fig. 5D, lane 2, S(LK)S) domains induced the expression of both Xbra and Xwnt8 at doses similar to those required for wild-type Laloo. Laloo chimeras with the Src SH3 (Fig. 5B, lane 1, L(S3)L); SH2 (Fig. 5C, lane 1, L(S2)L); or kinase (Fig. 5D, lane 1, L(SK)L) domains remained active. These data, summarized in Fig. 5E, indicate that the Laloo SH3, SH2, and kinase domains are independently sufficient to activate Src in the mesoderm induction assay but are not specifically necessary for Laloo activity.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 5.   Activity of Laloo-Src domain-swap hybrids. A-D, RT-PCR analysis of animal caps dissected at late blastula stages and cultured until midgastrula stages. 1 ng each of L4S, S4L, L(S3)L, S(L3)S, L(S2)L, S(L2)S, L(SK)L, and S(LK)S RNA were injected as listed. E, summary of Laloo-Src chimeric experiments described in this study. Laloo domains are boxes. Src domains are ovals. A positive score for mesoderm-inducing activity was defined as stimulation of both Xbra and Xwnt8 expression in gastrula stage animal cap explants.

Regulation of Src-Laloo Chimeras-- The chimeric analyses described above suggest important roles for multiple Src homology domains during Src kinase-mediated mesoderm induction. It remains possible, however, that the Src-Laloo chimeras are regulated differently and/or induce mesoderm via molecular mechanisms distinct from those that govern, or are governed by, the endogenous Src kinases. Such a possibility complicates the interpretation of these data. To address these issues, we next examined the upstream regulation of the Src-Laloo domain-swap mutants. We decided to focus on those Src constructs containing an activating Laloo region, because these display a striking alteration of function mediated solely by the exchange of a single functional domain. Thus, they are the constructs for which it is most critical to determine faithful intracellular regulation.

We have previously demonstrated that mesoderm induction by the Src-related kinases is inhibited by co-expression of a dominant inhibitory FGF receptor construct (XFD) (3, 4, 20). However, a constitutively active Laloo mutant in which the C-terminal regulatory tyrosine is mutated to phenlyalanine (Y492F) is insensitive to FGF receptor blockade, suggesting that signals downstream of the receptor dephosphorylate the C-terminal tyrosine residue and activate wild-type Laloo (3). As shown in Fig. 6, inhibition of FGF receptor signaling significantly inhibits mesoderm induction by the domain-swap mutants S(L3)S (compare lanes 1 and 2), S(LK)S (compare lanes 3 and 4), and S(L2)S (compare lanes 5 and 6). These data suggest that the chimeric molecules are not constitutively active and are regulated in a manner similar to that of Laloo.


View larger version (59K):
[in this window]
[in a new window]
 
Fig. 6.   Inhibition of Src-Laloo domain-swap hybrids by a dominant negative FGF receptor construct. RT-PCR analysis of animal caps dissected at late blastula stages and cultured until midgastrula stages. 1 ng each of S(L3)S, S(L2)S, and S(LK)S RNA, and 2 ng of a truncated FGF receptor construct (XFD, Ref. 20) were injected as listed. EF1-alpha was used as a loading control. Xbra is a panmesodermal marker. Chordin is a dorsal mesodermal marker. Xwnt8 is a ventrolateral mesodermal marker.

We next examined the molecular targets of the activated domain-swap mutants. We have shown that Laloo, but not Src, phosphorylates tyrosine residues on SNT-1 and that SNT-1 mutants lacking tyrosine phosphorylation sites block mesoderm induction by the Src kinases (Fig. 3 and Ref. 6). These data strongly suggest that the Src-related proteins induce mesoderm via the phosphorylation of SNT. In Fig. 7, we demonstrate that the activated Src domain-swap constructs S(L3)S (lane 3), S(LK)S (lane 5), and S(L2)S (lane 6), like Laloo (lane 1) but unlike Src (lane 2), phosphorylate SNT-1. Furthermore, mesoderm induction by these chimeric proteins is inhibited by co-expression of 6YF, an unphosphorylatable form of SNT-1 (data not shown). These results suggest that the activated domain-swap constructs used in this study induce mesoderm through the phosphorylation of SNT-1, in a manner similar to that of wild-type Laloo.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 7.   SNT-1 phosphorylation by activated Src-Laloo domain-swap hybrids. Western blot analysis of SNT-1 immunoprecipitation. Synthetic RNA from epitope-tagged constructs was injected into early cleavage stage embryos; 1 ng each of SNT-1-Myc, Laloo, Src, S(L3)S, S(LK)S, and S(L2)S RNA were injected as listed. Cell lysates were collected at late blastula stages. Myc-tagged SNT-1 protein was immunoprecipitated using an anti-Myc antibody. SNT-1 tyrosine phosphorylation was detected by Western blot (top lanes). Expression of Myc-tagged SNT-1 protein was determined by Western blot analysis of cell lysates (bottom lanes).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Members of the Src kinase family play an essential role in vertebrate mesoderm formation, functioning as mediators of a signaling cascade triggered by FGF receptor activation. Here, we have examined the basis for the differences in activity between the Src and Laloo kinases during mesoderm induction. We have shown that Src inactivity is likely a result of its inability to phosphorylate SNT-1 on tyrosine, an event that is required for mesoderm formation in vivo. Furthermore, our studies suggest that Src inactivity is mediated by the phosphorylation state of a C-terminal tyrosine residue and that this repression can be transposed to Laloo by exchange of a 15-residue region. Finally, we have demonstrated that the SH3, SH2, and kinase domains of Laloo may all confer additional specificity to this kinase during early development.

The observation that activated Src behaves biochemically and embryologically like Laloo suggests that Src inactivity during mesoderm formation may be due in part to repression of Src via Tyr-526. Such repression might be mediated by an inhibitory kinase that binds specifically to the C terminus of Src or by an activating phosphatase that binds preferentially to the Laloo C terminus. Although the C-terminal Src kinase (Csk) appears to inhibit both Laloo and Fyn and is thus not a good candidate for a Src-specific inhibitor, related kinases may be present in the early Xenopus embryo that fulfill this function (14). The SHP2 phosphatase is required for FGF-mediated mesoderm induction (21). Although SHP2 activity is required downstream of or in parallel to Laloo, the available data do not preclude additional involvement of SHP2 upstream of Laloo (4); thus, SHP2 may function as a preferential activator of a subset of Src family proteins, including Laloo.

Negative regulation of the Src kinases is mediated by a number of intramolecular interactions involving the SH3, SH2, and C-terminal domains of these molecules (22). The activity of our Laloo-Src chimeras thus likely reflects alterations in both intra- and intermolecular stability. LST may be inactive in part because the phosphorylated Src tail binds with more affinity than the Laloo tail to the Laloo SH2 domain. However, because activated Src but not SLT induces mesoderm, the Src SH2 appears to bind both the Laloo and Src tails with sufficient affinity to inhibit kinase function in these constructs. Further complicating such a scenario, L(S2)L is active, suggesting that SLT inactivity is not only due to interactions between the Src SH2 domain and the Laloo tail. When considered in aggregate, our results point to the contribution of inter- as well as intramolecular interactions underlying the differences in the ability of Src and Laloo to participate in the activation of a mesoderm-forming signaling cascade. SNT-1 is a substrate of the Laloo kinase, and Laloo-SNT-1 association requires the Laloo SH3 domain in a yeast 2-hybrid assay (this study and Refs. 5 and 6); thus, the differences we observe between the SH3 and kinase domains of Laloo and Src may reflect the differential ability of these molecules to bind and phosphorylate SNT-1. These distinctions would not be manifest during mesoderm formation in vivo, because C-terminal inhibition of Src would block its capacity to phosphorylate SNT-1.

    ACKNOWLEDGEMENTS

We thank Y. Song for excellent technical assistance and P. Wilson for critical reading of the manuscript.

    FOOTNOTES

* This work was supported by an Irma T. Hirschl Career Scientist Award, by the Speaker's Fund for Biomedical Research: Toward the Science of Patient Care, awarded by the City of New York, by the AMDeC (Academic Medicine Development Company) Foundation of New York City, through its Tartikoff/Perelman/Entertainment Industry Fund for Young Investigators in Women's Cancers, and by United States Public Health Service Grant R01-GM61671 (all to D. C. W.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Members of the graduate training program in molecular, cellular, biochemical, and developmental sciences.

§ To whom correspondence should be addressed: Dept. of Pharmacology and Biological Chemistry, Mount Sinai School of Medicine, 1 Gustave L. Levy Pl., Box 1215, New York, NY 10029. Tel.: 212-659-1721; Fax: 212-831-0114; E-mail: weinsd01@doc.mssm.edu.

Published, JBC Papers in Press, March 23, 2002, DOI 10.1074/jbc.M110637200

    ABBREVIATIONS

The abbreviations used are: FGF, fibroblast growth factor; bFGF, basic FGF; Xbra, Xbrachyury; SH, Src homology; L4S, Src with the Laloo SH4 domain; S4L, Laloo with the Src SH4 domain; L(S3)L, Laloo with the Src SH3 domain; S(L3)S, Src with the Laloo SH3 domain; L(S2)L, Laloo with the Src SH2 domain; S(L2)S, Src with the Laloo SH2 domain; L(SK)L, Laloo with the Src kinase domain; S(LK)S, Src with the Laloo kinase domain; LST, Laloo with the Src tail; SLT, Src with the Laloo tail; RT, reverse transcriptase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Klein, P. S., and Melton, D. A. (1994) Endocr. Rev. 15, 326-341[CrossRef][Medline] [Order article via Infotrieve]
2. Steele, R. E., Deng, J. C., Ghosn, C. R., and Fero, J. B. (1990) Oncogene 5, 369-376[Medline] [Order article via Infotrieve]
3. Weinstein, D. C., Marden, J., Carnevali, F., and Hemmati-Brivanlou, A. (1998) Nature 394, 904-908[CrossRef][Medline] [Order article via Infotrieve]
4. Weinstein, D. C., and Hemmati-Brivanlou, A. (2001) Dev. Dyn. 220, 163-168[CrossRef][Medline] [Order article via Infotrieve]
5. Kusakabe, M., Masuyama, N., Hanafusa, H., and Nishida, E. (2001) EMBO Rep. 8, 727-735[CrossRef]
6. Hama, J., Xu, H., Goldfarb, M., and Weinstein, D. C. (2001) Mech. Dev. 109, 195-204[CrossRef][Medline] [Order article via Infotrieve]
7. Kouhara, H., Hadari, Y. R., Spivak-Kroizman, T., Schilling, J., Bar-Sagi, D., Lax, I., and Schlessinger, J. (1997) Cell 89, 693-702[CrossRef][Medline] [Order article via Infotrieve]
8. Hadari, Y. R., Kouhara, H., Lax, I., and Schlessinger, J. (1998) Mol. Cell. Biol. 18, 3966-3973[Abstract/Free Full Text]
9. Xu, H., and Goldfarb, M. (2001) J. Biol. Chem. 276, 13049-13056[Abstract/Free Full Text]
10. Steele, R. E. (1985) Nucleic Acids Res. 13, 1747-1761[Abstract/Free Full Text]
11. Steele, R. E., Irwin, M. Y., Knudsen, C. L., Collett, J. W., and Fero, J. B. (1989) Oncogene Res. 1, 223-233
12. Hemmati-Brivanlou, A., and Melton, D. A. (1994) Cell 77, 273-281[CrossRef][Medline] [Order article via Infotrieve]
13. Wilson, P. A., and Hemmati-Brivanlou, A. (1995) Nature 376, 331-333[CrossRef][Medline] [Order article via Infotrieve]
14. Song, Y., Cohler, A. N., and Weinstein, D. C. (2001) Oncogene 20, 5210-5214[CrossRef][Medline] [Order article via Infotrieve]
15. Weinstein, D. C., Honore, E., and Hemmati-Brivanlou, A. (2001) Development 124, 4235-4242[Abstract]
16. Smith, J. C., Price, B. M. J., Green, J. B. A., Weigel, D., and Herrmann, B. G. (1991) Cell 67, 79-87[CrossRef][Medline] [Order article via Infotrieve]
17. Smith, W. C., and Harland, R. M. (1991) Cell 67, 753-765[CrossRef][Medline] [Order article via Infotrieve]
18. Christian, J. L., McMahon, J. A., McMahon, A. P., and Moon, R. T. (1991) Development 111, 1045-1055[Abstract/Free Full Text]
19. Brown, M., T., and Cooper, J., A. (1996) Biochim. Biophys. Acta 1287, 121-149[Medline] [Order article via Infotrieve]
20. Amaya, E., Musci, T. J., and Kirschner, M. W. (1991) Cell 66, 257-270[CrossRef][Medline] [Order article via Infotrieve]
21. Tang, T. L., Freeman, Jr., R. M., O'Reilly, A. M., Neel, B. G., and Sokol, S. Y. (1995) Cell 80, 473-483[CrossRef][Medline] [Order article via Infotrieve]
22. Superti-Furga, G. (1995) FEBS Lett. 369, 62-66[CrossRef][Medline] [Order article via Infotrieve]
23. Bassez, T., Paris, J., Omilli, F., Dorel, C., and Osborne, H. B. (1990) Development 110, 955-962[Abstract/Free Full Text]
24. Krieg, P., Varnum, S., Wormington, M., and Melton, D. A. (1989) Dev. Biol. 133, 93-100[CrossRef][Medline] [Order article via Infotrieve]
25. Sasai, Y., Lu, B., Steinbeisser, H., Geissert, D., Gont, L. K., and DeRobertis, E. M. (1994) Cell 79, 779-790[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
T. Haremaki, S. T. Fraser, Y.-M. Kuo, M. H. Baron, and D. C. Weinstein
Vertebrate Ctr1 coordinates morphogenesis and progenitor cell fate and regulates embryonic stem cell differentiation
PNAS, July 17, 2007; 104(29): 12029 - 12034.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. S. Ridyard and S. M. Robbins
Fibroblast Growth Factor-2-induced Signaling through Lipid Raft-associated Fibroblast Growth Factor Receptor Substrate 2 (FRS2)
J. Biol. Chem., April 11, 2003; 278(16): 13803 - 13809.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/22/19806    most recent
M110637200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hama, J.
Right arrow Articles by Weinstein, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hama, J.
Right arrow Articles by Weinstein, D. C.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.